Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25839664 | 0.92 | ADORA3 (0.34) | ADORA3ADORA2ACCNA2CDK2KDM4E | |
| SCHEMBL25427310 | 0.86 | ADORA3 (0.31) | ADORA3ADORA2A | |
| SCHEMBL25171014 | 0.83 | MKNK2 (0.33) | ADORA3ADORA2ACCNA2CDK2KDM4E | |
| SCHEMBL30410817 | 0.83 | MKNK2 (0.33) | ADORA3ADORA2ACCNA2CDK2KDM4E | |
| SCHEMBL25171015 | 0.83 | MKNK2 (0.33) | ADORA3ADORA2ACCNA2CDK2KDM4E | |
| SCHEMBL25171016 | 0.83 | MKNK2 (0.33) | ADORA3ADORA2ACCNA2CDK2KDM4E | |
| SCHEMBL25839656 | 0.83 | ALDH1A1 (0.33) | CCNA2CDK2KDM4EHPGDTSHR | |
| SCHEMBL30309823 | 0.82 | MDM2 (0.33) | CCNA2CDK2 | |
| SCHEMBL25839577 | 0.82 | ALDH1A1 (0.35) | CCNA2CDK2KDM4EHPGDTSHR | |
| SCHEMBL25171195 | 0.81 | JAK3 (0.33) | KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4163283-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | BTK, SRC, YES1 | ADORA3 1899/4885ADORA2A 4277/4885CCNA2 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.